Acusphere Inc. (ACUS)

Overview

Acusphere, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative cardiovascular drugs. Initially established as Polymers For Medicine, Inc., the company underwent a name change to Acusphere, Inc. in March 2004, signaling its refined focus and evolving identity in the pharmaceutical sector. Since its inception in 1993, Acusphere has been dedicated to addressing the critical needs in cardiac care through its advanced drug development programs. The company is headquartered in Watertown, Massachusetts, reflecting its deep roots and commitment to contributing to the vibrant biotechnology ecosystem in the region.

Products and Services

• Imagify (perflubutane polymer microspheres)

Imagify is Acusphere's flagship product, designed to significantly improve the diagnosis of coronary artery disease (CAD)—a leading cause of death worldwide. This cardiovascular drug operates as a novel diagnostic agent that evaluates myocardial perfusion, a critical factor in determining the heart's blood flow and overall function. By deploying a unique injectable suspension of perflubutane polymer microspheres, Imagify enables clinicians to detect CAD with enhanced accuracy, facilitating earlier and more effective intervention. Its innovative approach represents a notable advancement in cardiac diagnostic technology, offering a promising alternative to traditional diagnostic methods that are often more invasive, less accessible, or less accurate.